StemCell Therapy

July 27, 2018 - By Vernon Prom

Investors sentiment increased to 1.61 in Q1 2018. Its up 0.38, from 1.23 in 2017Q4. It is positive, as 24 investors sold Seattle Genetics, Inc. shares while 53 reduced holdings. 31 funds opened positions while 93 raised stakes. 159.52 million shares or 12.47% more from 141.83 million shares in 2017Q4 were reported.

California State Teachers Retirement System reported 165,312 shares. 13,084 are held by Bluecrest Cap Ltd. Pictet Asset invested in 0.1% or 786,323 shares. Swiss Bankshares owns 0.02% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 349,100 shares. Keybank National Association Oh invested in 0% or 8,414 shares. 4,998 were accumulated by Shell Asset Mngmt Company. Pnc Financial holds 6,727 shares. Utah Retirement Sys holds 0.02% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 19,600 shares. Wells Fargo And Co Mn, a California-based fund reported 306,681 shares. The Connecticut-based Bridgewater Associate L P has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Amundi Pioneer Asset Management has 21,523 shares. National Bank Of America Corp De accumulated 496,573 shares. Daiwa Securities accumulated 4,395 shares. Zurcher Kantonalbank (Zurich Cantonalbank), Switzerland-based fund reported 23,953 shares. Pub Employees Retirement Association Of Colorado invested in 20,183 shares or 0.01% of the stock.

Since February 1, 2018, it had 3 buys, and 12 sales for $266.62 million activity. Cline Darren S also sold $497,983 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) shares. The insider SIEGALL CLAY B sold 18,832 shares worth $951,393. The insider HIMES VAUGHN B sold 5,000 shares worth $290,604. 10,457 shares were sold by DRACHMAN JONATHAN G, worth $552,452.

JP Morgan now has a $77 target on the $11.55 billion market cap company or 5.51 % upside potential. In analysts note issued to clients on Friday, 27 July, Seattle Genetics (NASDAQ:SGEN) shares have had their Overweight Rating kept by professional analysts at JP Morgan.

Among 8 analysts covering Seattle Genetics (NASDAQ:SGEN), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Seattle Genetics has $77.0 highest and $60.0 lowest target. $68.13s average target is -6.65% below currents $72.98 stock price. Seattle Genetics had 12 analyst reports since January 31, 2018 according to SRatingsIntel. SunTrust maintained it with Hold rating and $60.0 target in Wednesday, February 7 report. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned Buy rating by Needham on Wednesday, February 7. J.P. Morgan upgraded the shares of SGEN in report on Wednesday, February 14 to Buy rating. The rating was maintained by Morgan Stanley on Wednesday, March 21 with Overweight. The firm has Buy rating by RBC Capital Markets given on Tuesday, March 20. The firm has Buy rating given on Monday, June 11 by SunTrust. The company was maintained on Wednesday, February 7 by H.C. Wainwright. On Thursday, February 1 the stock rating was maintained by H.C. Wainwright with Buy. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has Neutral rating given on Wednesday, February 7 by Bank of America. The firm has Overweight rating by JP Morgan given on Wednesday, February 14.

The stock increased 2.43% or $1.73 during the last trading session, reaching $72.98. About 1.60M shares traded or 72.55% up from the average. Seattle Genetics, Inc. (NASDAQ:SGEN) has declined 15.50% since July 28, 2017 and is downtrending. It has underperformed by 28.07% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $11.55 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Streetinsider.com which released: Seattle Genetics (SGEN) Adcetris On-going Launch in 1L cHL is Positive Says SunTrust. on July 02, 2018, also Benzinga.com with their article: Benzingas Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold published on July 26, 2018, Seekingalpha.com published: Mid-stage study underway for Seattle Genetics tisotumab vedotin in solid tumors; shares up 1% premarket on July 12, 2018. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Seekingalpha.com and their article: Dont Sell Axon Enterprise Cramers Lightning Round (7/11/18) published on July 12, 2018 as well as Benzinga.coms news article titled: Benzingas Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgens Beat-And-Raise Quarter with publication date: July 27, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the original post here:
TOday's Movers: Seattle Genetics (NASDAQ:SGEN) Stock ...

This entry was posted on July 29, 2018 at 1:43 am and is filed under Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |